TGFB1 and glioblastoma: In our study, we observed that M/A treatment of glioblastoma-bearing mice decreased the expression of TGF-β1 by approximately 3-fold compared to the untreated mice (Figure 2J), which is direct evidence of its anti-inflammatory effect and indirect evidence of its anti-fibrotic effect.